Business
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”)
About this update from Immix Biopharma, Inc.
[{"type":"text","content":"LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2023 in Haematologica highlighting NXC-201 in the context of the current U.S. Food And Drug Administration (“FDA”) approved BCMA CAR-T Cell therapies. \"The study [of NXC-201] shows a good safety profile, overall similar to other BCMA CAR T cell phase I-II studies, and similar efficacy, albeit with shorter follow-up, to that initially reported with the later FDA-approved BCMA CAR T cells (75% overall response rate [85% ORR in the group given the highest CAR T cell dose] compared with 85% in the phase I trial evaluating ide-cel [marketed as ABECMA® by Bristol Myers Squibb] and 97% in the phase 1b/II trial for cilta-cel [marketed as CARVYKTI® by Janssen/Johnson & Johnson]),” the authors Maria Sjöstrand and Michel Sadelain stated. “[Furthermore, the NXC-201] trial included nine patients who had relapsed after treatment with an anti-BCMA antibody, belantamab mafodotin, prior to receiving HBI0101, which the authors suggested may be associated with a less favorable response to CAR therapy.” The title of the editorial is, “Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma,” published in Haematologica Early View, available at www.nexcella.com/publications. To date, 58 patients have been treated with NXC-201, 50 in multiple myeloma, and 8 in AL amyloidosis. The $13.9 billion Multiple Myeloma market in 2017 is expected to reach $28.7 billion in 2027 according to Wilcock, et al. Nature Reviews. About NXC-201 NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. The design consists of a structurally differentiated CAR-T with our proprietary BCMA-targeting CAR which has demonstrated reduced toxicity in NEXICART-1, supporting investigating NXC-201 as an outpatient therapy. As of the October 23, 2022 data cutoff, updated clinical data in 47 patients from the ongoing Phase 1b/2a portion of the NEXICART-...